<DOC>
	<DOC>NCT02559544</DOC>
	<brief_summary>Evaluate [18F]FES PET/CT uptake as a predictor of progression free survival in endocrine refractory recurrent or metastatic breast cancer patients starting a new therapy regimen including endocrine targeted therapy.</brief_summary>
	<brief_title>[18F]Fluoroestradiol (FES) PET/CT Imaging to Evaluate in Vivo Estrogen Receptor Activity in Endocrine Refractory Recurrent or Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>1. At least 18 years of age 2. Recurrent or metastatic cancer that is of known or suspected breast origin may be biopsy proven or identified on standard imaging (e.g. CT, bone scan, MRI, FDG PET/CT) 3. History of ER+ pathology (ER+ may be confirmed from surgery or biopsy of primary breast cancer or lymph nodes, and/or surgery or biopsy of a metastatic site, metastatic biopsy is not required) 4. At least one site of disease outside of the liver that is seen on standard imaging (e.g. CT, bone scan, MRI, FDG PET/CT); patients with measurable or nonmeasurable disease are allowed. 5. History of progression or recurrence of disease while on an endocrine targeted therapy containing regimen as assessed by medical record review of breast cancer history at screening 6. Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to studyspecific procedures. 1. Females who are pregnant at the time of screening will not be eligible for this study, urine pregnancy test will be performed at screening in women of childbearing potential. 2. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician 3. Serious or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study. 4. History of HER2/neu positive cancer (IHC 3+ and/or FISH positive) as assessed by medical record review at screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>failed prior endocrine therapy</keyword>
</DOC>